Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BMO Capital Starts Pfizer at Outperform With $60 Price Target

11/19/2021 | 05:57am EST


© MT Newswires 2021
All news about PFIZER, INC.
03:49pBritain to distribute new Pfizer COVID-19 antiviral drug Paxlovid
AQ
11:38aGerman Regulator Head Backs Pfizer-BioNTech's COVID-19 Vaccine Trial In US
MT
11:01aPfizer Receives European Commission's Approval for Lung Cancer Drug Lorviqua
MT
10:48aGerman regulator supports BioNTech/Pfizer's U.S. vaccine trial
RE
10:23aPfizer Secures European Commission's Approval for Lung Cancer Drug Lorviqua
MT
10:14aPfizer Gets EC OK for Lorviqua as First-Line Treatment for ALK-Positive Advanced Lung C..
DJ
09:47aEuropean Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-P..
BU
09:06aBritain to start rolling out Pfizer COVID pill next month
RE
08:59aEU ombudsman slams executive arm over vaccine communication
AQ
07:27aMERCK : Molnupiravir Covid-19 Pill Effective Against Omicron in Lab Tests
DJ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 791 M - -
Net income 2021 22 567 M - -
Net Debt 2021 29 165 M - -
P/E ratio 2021 14,0x
Yield 2021 2,97%
Capitalization 300 B 300 B -
EV / Sales 2021 4,02x
EV / Sales 2022 3,01x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 53,37 $
Average target price 58,07 $
Spread / Average Target 8,81%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-9.62%299 559
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960
ELI LILLY AND COMPANY-13.89%214 609